2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Bacterial, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4455 Characterization of skin cancer in patients with SMAD4 mutation in hereditary hemorrhagic telangiectasia: Risk assessment for a rare genetic vasculopathy

Ruhi Kanwar, MD, Sam Schepps, MD2, Brianna Spiegel, BS3, Nancy Anabaraonye, BA4, Sarah Schultz, BA5, Georgiana McTigue, BA6, Kevin Fettel, MSc7, Vinod E Nambudiri, MD MBA MPH EdM8
1 Brigham & Women's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 University of Maryland School of Medicine, Baltimore, Maryland, United States
3 Boston University School of Medicine, Boston, Massachusetts, United States, Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States
4 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
5 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Medical College of Georgia, Athens, Georgia, United States
6 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
7 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
8 Brigham & Women's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

SMAD4 is a protein that acts as a common mediator of the transforming growth factor-B (TGF-B) superfamily, essential for signaling. There has been growing evidence of its role with skin cancer. Mouse models have shown that it is a suppressor in skin tumorigenesis, with disruption leading to early onset of skin cancer, due to increased proliferation and reduced apoptosis of follicular keratinocytes. (Tang et al, Cancer Research, 2005) Additionally, in vivo study has shown that SMAD4 loss increases UV-induced skin carcinogenesis. (Mitra et al, Journal of Invest Derm, 2013) Interestingly, mutations in the SMAD4 gene are a rare real-world occurrence in clinical medicine with hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vasculopathy; as low as <2% of clinically suspected HHT have been detected to be SMAD4. (Tabosh et al, J Clin Invest, 2024) (Inoguchi et al, Intern Med, 2018) This hematological disease has manifestations of epistaxis, skin telangiectasias, pulmonary arteriovenous malformations (AVMs), digestive telangiectasias, hepatic AVMs. (Caillot et al, J of Medical Genetics, 2024) Despite the evidence of SMAD4’s potential potent tumor suppressor role in skin cancer and frequent loss in squamous cell carcinomas, (Hernandez et al, Molecular Carcinogenesis, 2019) investigation into cutaneous neoplastic risk in the HHT-SMAD4 variant has not been performed. Thus, this retrospective study aimed to investigate the risk of skin cancer in patients with SMAD4 mutant HHT.

The Brigham and Women’s Hospital and Massachusetts General Hospital patient registry was queried from 1979 to March 2025 for charts with HHT in any clinical documentation. Chart review was conducted to confirm both SMAD4 mutation and HHT diagnosis. Of 1753 patients, 31 patients met inclusion criteria. Additionally, the included patients had corresponding matched patients queried by age, sex, and race 1:1. Multivariable logistic regression analysis (adjusted for age, sex, smoking history, and family history of skin cancer) was conducted using R.

The majority of SMAD4 mutant patients with HHT were female (58.1%), white (77.4%), and non-Hispanic (74.2%). A total of 2 patients had basal cell carcinoma (6.5%) and 1 patient had squamous cell carcinoma (3.2%). There were no occurrences of melanoma or other skin cancer within the SMAD4 mutant group. When comparing the two cohorts, there was no increased risk of skin cancer between patients with HHT and SMAD4 mutation compared to patients without HHT who were their corresponding matches (adjusted odds ratio 0.617, 95% CI 0.108-3.608, p=0.622).  

Our study describes one of the largest cohorts (Caillot et al, J of Medical Genetics, 2024) of SMAD4 variants, including in the context of HHT. Such investigation aimed to address risk assessment for this rare genetic population, so patients and providers can have context and data. Despite preclinical evidence that disruption of SMAD4 leads to early skin cancer development, our findings suggest that patients with HHT who have the SMAD4 mutation, do not have an increased risk of skin cancer, including squamous cell carcinoma. Limitations of this study include retrospective design, sample size, and use of a single health care system. Future investigation, including larger cohort analysis, is needed. Additionally, further in vivo studies, adding to the potential role of heterozygosity and pathway elucidation are warranted.

Ruhi Kanwar, MD: No relevant conflicts of interest to declare.